Bradley J. Monk, MD, FACS, FACOG, discusses the utility of tisotumab vedotin in recurrent cervical cancer.
Bradley J. Monk, MD, FACS, FACOG, US oncology medical director of Gynecologic Oncology Research and a professor at the University of Arizona College of Medicine, discusses the utility of tisotumab vedotin in recurrent cervical cancer.
The world of gynecologic oncology is populated with antibody-drugs conjugates (ADCs), says Monk. For example, tisotumab vedotin, which was developed via a collaboration between Genmab and Seattle Genetics, is an ADC against tissue factor. Tissue factor is a very important tumor-specific antigen that is overexpressed in virtually every recurrent case of cervical cancer, says Monk.
The idea is to take patients who have recurrent cervical cancer, treat them with this ADC, that will then bind and localize in the tumor. Not only will tisotumab vedotin kill the cancer that it binds to, but there will also be a standby effect, concludes Monk.